Europe Misses the Takeoff of Its Biotech Startups

An American biotechnology startup receives on average several times more late-stage funding than its European equivalent. This disparity reveals a structural deficit that pushes young European companies toward exile or extinction. While Europe debates, America and Asia are capturing tomorrow’s talent and patents.

Europe’s biotechnological ecosystem suffers from a chronic ailment: its most promising startups are fleeing to more favorable horizons. This silent hemorrhage testifies to a worrying disconnect in the face of international competition.

The Essentials

  • American biotech startups capture several times more late-stage funding than their European counterparts
  • Clinical trial authorizations take longer in Europe than elsewhere
  • A growing number of European startups are considering relocation

Europe Misses the Decisive Funding Rounds

The European problem begins precisely when a biotech startup demonstrates its potential. Early funding rounds (Series A and B) are still negotiated at parity between Europe and its competitors. But starting with Series C—the round that finances Phase III clinical trials and market launch—the gap widens dramatically.

A European biotechnology startup raises on average significantly lower amounts during its Series C round compared to an equivalent American company. This disparity is explained by the reluctance of European institutional investors to take on biotechnology risk and the absence of specialized funds of critical size.

The example of Moderna illustrates this difference in approach. Founded in 2010, the American biotech raised 2.6 billion dollars before commercializing a single product. In Europe, no startup has ever approached such amounts in the pre-commercial phase. BioNTech, often cited as a European success story, had to raise its largest financings in the United States through its partnership with Pfizer.

This shortage of late-stage capital forces European startups into binary choices: accept derisory valuations or emigrate. Cambridge-based Kymab was acquired by Sanofi for 1.1 billion dollars in 2021, a price its founders consider undervalued compared to American standards.

European Bureaucracy Discourages Innovation

Beyond financing, Europe imposes on its biotech startups an administrative obstacle course. The authorization of multinational clinical trials—essential for constituting sufficient patient cohorts—requires more time in the EU than in the United States or South Korea.

This slowness is explained by European regulatory fragmentation. Despite the harmonization promised by the 2014 European Clinical Trials Regulation, each member state retains its own documentary requirements and review timelines. A startup wishing to test its treatment in France, Germany, and Italy must navigate between three distinct administrative systems, with certified translations and different points of contact.

The digitization of procedures also lags considerably. When the American FDA processes the vast majority of files through its unified electronic platform, European agencies still largely operate through postal mail and email exchanges. This administrative inefficiency costs startups hundreds of thousands of additional euros per European clinical trial.

The impact is measured in lost months. In the biotechnology race, where patents expire and international competition intensifies, these administrative delays can determine the commercial success or failure of a treatment. Several biotech executives cite this procedural burden as the primary factor in their relocation decisions.

Asia Captures European Talent with Targeted Incentives

Singapore and South Korea understood the opportunity created by European dysfunctions. These countries deploy attraction programs specifically designed for European biotechnology startups struggling with financing difficulties or bogged down in administrative procedures.

These attraction strategies work. A growing number of European biotechnology startups are relocating to Asia. These expatriate companies take with them their patents, their research teams, and their European academic partnerships.

The Brain Drain Redraws the Global Pharmaceutical Innovation Map

This migration of European biotech startups redistributes the cards of global pharmaceutical innovation. The United States and Asia no longer merely attract established companies: they are capturing entire research ecosystems.

When a biotech startup emigrates, it takes with it its partnerships with European university laboratories, its contracts with investigator hospitals, and its licensing agreements with public research institutions. This dynamic progressively impoverishes Europe’s ecosystem of its most innovative connections.

The impact is already visible in patenting statistics. European biotechnology patent filings are declining, while they are progressing significantly in the United States and Asia. This divergence suggests that Europe is losing not only its startups, but also its capacity for innovation in the sector.

The long-term health consequences remain difficult to quantify, but several warning signals are emerging. Europe is now accumulating an increasing lag in access to new biotechnology therapies. This deterioration is explained by the priority given by expatriate startups to American and Asian markets for their commercial launches.

In a sector where first-mover advantage is decisive, this lag could prove irreversible for a generation of biotechnological innovations.